AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) Announces Closing of Public Offering
Published: Jan 24, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported that it has closed its recently announced public offering of common stock. The total number of shares sold was 7,667,050, comprised of 6,667,000 shares of common stock initially offered and an additional 1,000,050 shares of common stock sold pursuant to the underwriters' exercise of their over-allotment option, at the public offering price of $7.50 per share. Aggregate net proceeds to the company were approximately $53.8 million, after deducting underwriting discounts and commissions and estimated offering expenses. J.P. Morgan Securities LLC acted as sole book-running manager for the offering, with RBC Capital Markets, LLC and Canaccord Genuity Inc. acting as co-lead managers.